<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04258761</url>
  </required_header>
  <id_info>
    <org_study_id>210-9451-202</org_study_id>
    <nct_id>NCT04258761</nct_id>
  </id_info>
  <brief_title>A Safety and Tolerability Study of 10XB-101 Injections in Adult Subjects With Extra Fat Under the Chin (&quot;Double Chin&quot;)</brief_title>
  <official_title>A Multi-Center, Open Label, Single Ascending Dose Safety and Tolerability Study of Subcutaneously Administered 10XB-101 in Adult Subjects With Excessive Submental Fat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>10xBio, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>10xBio, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to find out more about an investigational drug,
      10XB-101, for people with fat under their chin which they would like to remove. The Sponsor
      of this study thinks there may be a chance this drug could be used to dissolve, or &quot;melt&quot;
      this fat away.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multi-center, open label, single ascending dose comparison.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 weeks</time_frame>
    <description>Incidence (severity and causality) of any local and systemic Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Skin Reactions (LSR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>At each time point, the number of subjects with presence (and severity) of the following LSRs on a 4 point scale (zero to 3), with a higher score indicating a worse outcome: erythema, edema, tenderness on palpation, bruising, pain, and stinging/burning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinician Submental Fat Scale (CSFS)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from Baseline in the CSFS on a five-point scale (zero to 4), with a higher score indicating a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Submental Fat Scale (PSFS)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from Baseline in the PSFS on a five-point scale (zero to 4), with a higher score indicating a worse outcome</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Submental Fat</condition>
  <arm_group>
    <arm_group_label>10XB-101 Solution for Injection 1.25% and 2.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 10XB-101 Solution for Injection, 1.25% or 2.0% via subcutaneous injection up to 10 mL on Day 1 of subject participation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10XB-101 Solution for Injection</intervention_name>
    <description>Active test article</description>
    <arm_group_label>10XB-101 Solution for Injection 1.25% and 2.0%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a male or non-pregnant female 18-65 years of age

          -  Signed informed consent

          -  Subject has a score of 2 or 3 on the Clinician Submental Fat Scale (CSFS) at Visit
             2/Baseline

          -  Subject is in good general health

        Exclusion Criteria:

          -  Loose skin or prominent platysmal bands in the neck or chin area

          -  Recent treatment with anticoagulants

          -  Presence of clinically significant health problems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Dobak, MD</last_name>
    <role>Study Director</role>
    <affiliation>10xBio, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Russell Smiley</last_name>
    <phone>858-571-1800</phone>
    <email>clinicalresearch@therapeuticsinc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 01</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Russ Smiley</last_name>
      <email>clinicalresearch@therapeuticsinc.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

